McKesson buying Irish wholesaler; BMS announces dividend;

@FiercePharma: India's Sun Pharma makes $48M purchase of eyecare firm InSite Vision. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo officially rejects Mylan's 'insulting,' 'ego'-driven buyout offer. Item | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) has declared a quarterly dividend of 37 cents per share payable November 2 to stockholders of record at the close of business on October 2. Report

> Drug wholesaler McKesson ($MCK) has a deal to buy the pharmaceutical distribution division of UDG Healthcare, based in Northern Ireland and the Republic of Ireland, for €408 million in cash. Release

> Swiss health authorities have approved Novartis' ($NVS) Entresto. Release

> Mylan ($MYL) has launched a generic version of Novartis cholesterol med Lescol XL. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: U.K. scientists develop ultrasonic device to better clean medical instruments. Article | Follow @FierceMedDev

@EmilyWFierce: Jaychem Industries is feeling the burn from an FDA warning letter over its GolfersSkin Sunscreen. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Penumbra goes public in upsized $120M deal, med tech's largest IPO of 2015. Story

> Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article

> FDA cautions against improperly cleaned bronchoscope devices. More

Biotech News

@FierceBiotech: RegenX IPO raises $138M, renewing hopes for a big Q4 biotech run. Article | Follow @FierceBiotech

@JohnCFierce: Allergan and Richter win FDA approval for a once-rejected schizophrenia pill. News | Follow @JohnCFierce

> NIH pushes forward in Obama's $215M 'precision medicine' plan. News

> Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D. Story

> FierceBiotech Radio on 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic. More